HIV, which causes acquired immune deficiency syndrome (AIDS), invades the host cell via the CD4 receptor and CCR5 or CXCR4 co-receptors. Interferons induced early in HIV infection induce an antiviral defense mechanism through IFNAR signaling. Our study aimed to examine the relationship between CCR5, CXCR4, and IFNAR1 gene variations as a risk factor in HIV + patients and their response to their clinical parameters. Targeted next-generation sequencing (tNGS) was used to perform molecular genotyping analysis of the CCR5, CXCR4, and IFNAR1 genes in genomic DNA from 22 HIV + patients and 25 healthy individuals as controls. We detected 13 rare mutations in the study, including 3 missense, 1 synonymous, 2 5′UTR, 4 3′UTR, and 1 frameshift variation. We also analyzed 6 common variants in the IFNAR1 and CXCR4 genes. HIV + patients carrying the homozygous TT genotype of the IFNAR1 intronic rs2856973:T > A variant had higher CD4 + T cell counts compared with patients carrying the TA + AA genotypes of the rs2856973 variant in the naive and first month of the ART (p = 0.001 and p = 0.001, respectively). Similarly, participants receiving ART with a TT genotype of rs2856973:T > A showed a significantly higher CD4 + T cell count in the third month (p = 0.001). Patients carrying the homozygous wild-type genotype of the CXCR4 intronic rs2680880:A > T SNP had lower CD4 + T cell count compared with subjects carrying the AT + TT mutant genotypes of rs2680880:A > T in the naive and first-month period (p = 0.015 and p = 0.025, respectively). Our results demonstrate that intronic variations in the IFNAR1 rs2856973:T > A and CXCR4 rs2680880:A > T genes can contribute to modifications in HIV progression and CD4 + T recovery under ART.
29 July 2025 in Psychiatry and Clinical Psychopharmacology
Background: This study aims to investigate the effects of vitamin B12 on morphine-induced conditioned place preference (CPP), a model commonly used to assess the rewarding effects of drugs. Morphine is a potent analgesic widely used for moderate to severe pain, but it also poses a significant risk of addiction. Previous studies suggest that cyanocobalamin (vitamin B12) may enhance the analgesic effects of morphine and reduce tolerance, but its impact on morphine addiction remains unclear. Methods: The experiment followed phases of habituation, pre-conditioning, conditioning, and post conditioning. Adult male Wistar albino rats (250-300 g) were randomly divided into 3 groups (n=8 per group): control (saline), morphine (10 mg/kg), and a combination group of vitamin B12 (2 mg/kg) with morphine. The effects of saline, morphine, and the morphine-vitamin B12 combination on CPP were assessed. All drugs and saline were administered intraperitoneally (ip). Results: Morphine (10 mg/kg) significantly induced CPP compared to the saline group (P < .0001). Vitamin B12 (2 mg/kg) did not produce a statistically significant difference in morphine-induced CPP compared to the control group. Conclusion: Morphine induces a significant place preference, and vitamin B12 did not produce a statistically significant difference in reducing this effect. Further research with different doses of vitamin B12 is necessary to fully investigate these effects.